Report Details:
15 Companies Covered
209 Pages
Rising Prevalence of Chronic Diseases to Drive the Global Biosimilars Market at a CAGR of 20.35% During the Forecast Period 2025 to 2035
Market Research Future (MRFR) has published a cooked research report on the “Global Biosimilars Market”, which contains detailed information from 2019 to 2035. The Global Biosimilars Market is estimated to register a CAGR of 20.35% during the forecast period of 2025 to 2035.
MRFR recognizes the following companies as the key players in the Global Biosimilars Market — Pfizer, Generium, Sandoz, Roche, APOTEX, Samsung Bioepis, Boehringer Ingelheim, Eli Lilly, Accord Healthcare, Mylan, Teva Pharmaceuticals, Zydus Cadila, Bristol-Myers Squibb, Celltrion, and Amgen.
Market Highlights
The Global Biosimilars Market is accounted for to register a CAGR of 20.35% during the forecast period and is estimated to reach USD 282.30 Billion by 2035, up from USD 36.79 Billion in 2024.
The market growth is driven by the increasing prevalence of chronic diseases, cost-effectiveness of biosimilars, and supportive regulatory frameworks that accelerate product approvals and market penetration. Biosimilars offer affordable alternatives to expensive biologic drugs, making healthcare more accessible and sustainable.
Rising healthcare expenditure, technological advancements in biomanufacturing, and growing acceptance of biosimilars across therapeutic areas such as oncology, autoimmune, and infectious diseases are key contributors to market expansion. Additionally, emerging economies such as India, Brazil, and China are expected to play a crucial role in driving demand due to government support and increasing healthcare access.
Regulatory agencies including the FDA and EMA have established clear biosimilar approval pathways, ensuring product safety, efficacy, and patient trust. This regulatory clarity continues to encourage pharmaceutical companies to invest in biosimilar research and development.
Segment Analysis
The Global Biosimilars Market has been segmented based on Drug Class, Application, Route of Administration, and Distribution Channel.
Based on Drug Class, the market includes Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Bevacizumab, Trastuzumab, Ustekinumab, Tocilizumab, Aflibercept, Dupilumab, Denosumab, Others), Insulin, Granulocyte Colony-Stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Anticoagulants, and Others.The Monoclonal Antibodies segment dominated the market in 2024 and is projected to be the fastest-growing segment during the forecast period. This is due to their high therapeutic efficacy, targeted treatment capabilities, and favorable reimbursement policies.
Based on Application, the market includes Oncology (Breast Cancer, Lung Cancer, Prostate Cancer, Leukemia, Bladder Cancer, Colorectal Cancer, Others), Autoimmune Diseases, Infectious Diseases, Blood Disorders, and Others.The Oncology segment held the largest share in 2024 and is expected to continue its dominance, driven by the increasing global burden of cancer and the rising number of biosimilars targeting oncology therapies.
Based on Route of Administration, the market is divided into Subcutaneous and Intravenous.The Intravenous (IV) segment led the market in 2024 due to its wide use in hospitals for biologics requiring precise dosing, while the Subcutaneous segment is projected to grow fastest, supported by growing demand for patient self-administration and convenience.
Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Pharmacies.The Hospital Pharmacies segment dominated in 2024 due to the concentration of biologic therapies administered in clinical settings. However, the Online Pharmacies segment is expected to expand rapidly as digital health adoption and e-prescription systems increase globally.
Region Analysis
By Region, the Biosimilars Market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East & Africa.North America led the market in 2024, valued at USD 6.1 Billion, supported by robust healthcare infrastructure, strong regulatory oversight, and rapid biosimilar adoption.Asia Pacific is projected to be the fastest-growing region through 2035 due to expanding healthcare access, cost-sensitive patient populations, and government initiatives promoting biosimilar use.
Key Findings of the Study
• The Global Biosimilars Market is expected to reach USD 282.30 Billion by 2035, at a CAGR of 20.35% during the forecast period.• North America accounted for the largest market share in 2024.• Monoclonal Antibodies were the dominant Drug Class in 2024 and are projected to be the fastest-growing segment.• Oncology was the leading Application segment in 2024.• Hospital Pharmacies were the largest Distribution Channel in 2024, while Online Pharmacies are expected to witness the fastest growth.• Pfizer, Sandoz, Roche, Samsung Bioepis, and Amgen are among the leading players shaping the competitive landscape.
Related Reports
https://www.marketresearchfuture.com/reports/biosimilars-market-1329